Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute Hegenbart

Showing results (61-70 of 237) with videos related to

Pageof 24
Sort By:
Blood|August 19, 2007
Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host diseaseThomas Luft, Michael Conzelmann, Axel Benner, et al.
Hemasphere|February 21, 2022
Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosisNora Liebers, Stefan O Schönland, Claudius Speer, et al.
Annals of Hematology|August 1, 2008
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasoneUlrike Klein, Florentina Kosely, Jens Hillengass, et al.
Experimental Hematology|October 23, 2012
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding studyChristine Wolschke, Thomas Stübig, Ute Hegenbart, et al.
American Journal of Hematology|April 25, 2025
Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ InvolvementTobias Dittrich, Timon Hansen, Christoph R Kimmich, et al.
Critical Reviews in Oncology/Hematology|October 11, 2005
Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemiasDietger Niederwieser, Chiara Gentilini, Ute Hegenbart, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 11, 2011
Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensitySascha Dietrich, Mindaugas Andrulis, Ute Hegenbart, et al.
International Journal of Cardiology|August 14, 2014
Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosisArnt V Kristen, Moritz Biener, Ute Hegenbart, et al.
Bone Marrow Transplantation|January 20, 2026
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphomaIsabelle Krämer, Laila König, Arne Brecht, et al.
Leukemia & Lymphoma|March 31, 2021
Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD)Daniel Authier, Ute Hegenbart, Fabian Pohl, et al.
Pageof 24

Showing results (61-70 of 237) with videos related to

Sort By:
Pageof 24
Blood|August 19, 2007
Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host diseaseThomas Luft, Michael Conzelmann, Axel Benner, et al.
Hemasphere|February 21, 2022
Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosisNora Liebers, Stefan O Schönland, Claudius Speer, et al.
Annals of Hematology|August 1, 2008
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasoneUlrike Klein, Florentina Kosely, Jens Hillengass, et al.
Experimental Hematology|October 23, 2012
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding studyChristine Wolschke, Thomas Stübig, Ute Hegenbart, et al.
American Journal of Hematology|April 25, 2025
Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ InvolvementTobias Dittrich, Timon Hansen, Christoph R Kimmich, et al.
Critical Reviews in Oncology/Hematology|October 11, 2005
Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemiasDietger Niederwieser, Chiara Gentilini, Ute Hegenbart, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 11, 2011
Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensitySascha Dietrich, Mindaugas Andrulis, Ute Hegenbart, et al.
International Journal of Cardiology|August 14, 2014
Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosisArnt V Kristen, Moritz Biener, Ute Hegenbart, et al.
Bone Marrow Transplantation|January 20, 2026
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphomaIsabelle Krämer, Laila König, Arne Brecht, et al.
Leukemia & Lymphoma|March 31, 2021
Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD)Daniel Authier, Ute Hegenbart, Fabian Pohl, et al.
Pageof 24